Servier Partners with Klineo to Enhance Clinical Trial Access for Patients
核心洞察
Servier has partnered with Klineo (搜索) to improve patient access to information about ongoing clinical trials, particularly for rare cancers (搜索), using Klineo's digital platform.
The collaboration aims to reduce inequalities in access to therapeutic innovations by providing real-time information on suitable clinical trials to patients in France.
Initially focusing on Servier's oncology clinical trials in France, the partnership may expand to other countries after evaluating initial feedback.
Servier has announced a partnership with Klineo (搜索), a digital technology start-up, to improve access to and knowledge of ongoing clinical trials for patients. The collaboration is a key component of Servier’s digital health strategy, WeHealth by Servier, and aims to address the challenges patients face in finding suitable clinical trials, especially in rare diseases.
Klineo (搜索)'s digital platform offers an accessible and intuitive tool that enables patients and specialists to quickly identify relevant clinical trials in France. Through a dedicated digital interface, patients receive real-time updates on therapeutic opportunities that match their profile. The primary goal is to enhance the accessibility of information on available clinical trials, particularly in rare cancers (搜索) where patient recruitment poses a significant hurdle.
Enhancing Patient Access to Clinical Trials
According to Sophie Garnault, Director of Oncology Clinical Operations at Servier, this initial venture with Klineo (搜索) will allow Servier to "validate the suitability of this particular method and consider expanding it to a larger number of studies, covering more extensive geographical areas outside France."
Magali Moutte, Project Director for Servier’s WeHealth Digital Factory, stated, "Our collaboration with Klineo (搜索) is a clear reflection of our commitment to putting patients at the heart of our clinical strategy and using the power of technology to deliver effective solutions and drive patient recruitment. And by making information on clinical studies more readily available, we’re helping to reduce inequalities in access to therapeutic innovations."
Initial Focus and Future Expansion
Currently, the platform will feature only Servier’s oncology clinical trials in France. Following an evaluation of initial feedback, Servier plans to consider expanding the service to other countries. Thomas Peyresblanques, President of Klineo (搜索), noted that "Our partnership with Servier will allow us to benefit from the clinical research expertise of its employees and directly support our mission to provide all patients with access to therapeutic innovations."
This partnership underscores the growing importance of digital health solutions in improving patient access to clinical trials and therapeutic innovations, particularly in areas with high unmet medical needs such as rare cancers (搜索).